



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Zalipsky and Kiwan

APPLICATION No.: 10/723,473

FILED: November 26, 2003

FOR: **RELEASABLE LINKAGE AND
COMPOSITIONS CONTAINING SAME**

EXAMINER: Unassigned

ART UNIT: 1637

CONF. NO: 7930

**Information Disclosure Statement Within Three Months of
Application Filing or Before First Action – 37 C.F.R. § 1.97(b)**

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last (37 C.F.R. § 1.97(b)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- ☒ Copies of the following references are enclosed:
 - ☒ Reference No. 11
- ☒ Copies of the following references can be found in parent U.S. Application No. 09/556,610:
 - ☒ Reference Nos. 10, 12, 13-31
- ☒ This application was filed after June 30, 2003, therefore copies of U.S. patents or published applications are not required.

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).


Respectfully submitted,

Date: June 18, 2004

Judy M. Mohr
Judy M. Mohr
Registration No. 38,563

Correspondence Address:

Customer No. 22918
(650) 838-4300

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**Form PTO-1449 (Modified)
(Use several sheets if necessary)**COMPLETE IF KNOWN**

Application Number	10/723,473
Confirmation Number	7930
Filing Date	November 26, 2003
First Named Inventor	Zalipsky & Kiwan
Group Art Unit	1637
Examiner Name	Unassigned
Attorney Docket No.	55325-8167.US02

Set 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code			
	1	4179337		Davis, <i>et al.</i>	12/18/79	
	2	4766106		Katre, <i>et al.</i>	8/23/88	
	3	4902502		Nitecki, <i>et al.</i>	02/20/90	
	4	4917888		Katre, <i>et al.</i>	04/17/90	
	5	4935465		Garman	06/19/90	
	6	5103556		Filip, <i>et al.</i>	04/14/92	
	7	5395619		Zalipsky, <i>et al.</i>	03/07/95	
	8	5631018		Zalipsky, <i>et al.</i>	05/20/97	
	9	5891468		Martin, <i>et al.</i>	04/06/99	

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
	10	EP	0 317 957	B1	Senter	5/31/89		
	11	EP	0 510 197	A1	Seki, <i>et al.</i>	10/28/92		
	12	WO	98/16201*		Zalipsky, <i>et al.</i>	4/23/98		


OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	13	Brois, S.J., <i>et al.</i> , <i>J. Amer. Chem. Soc.</i> <u>92</u> (26):7629-7631 (1970).	
	14	Dittmer, J.C., <i>et al.</i> , <i>J. Lipid Res.</i> 126-127 (1964).	
	15	Ellman, G.I., <i>Arch. Biochem Biophys</i> <u>82</u> :70, (1959).	
	16	Gaber, M., <i>et al.</i> , <i>Pharmaceutical Res</i> <u>12</u> (10):1407-1416, (1995).	
	17	Grassetti and Murray, <i>Arch. Biochem Biophys</i> <u>119</u> :41, (1967).	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

 INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) Use several sheets if necessary				COMPLETE IF KNOWN	
				Application Number	10/723,473
				Confirmation Number	7930
				Filing Date	November 26, 2003
				First Named Inventor	Zalipsky & Kiwan
				Group Art Unit	1637
				Examiner Name	Unassigned
Attorney Docket No.	55325-8167.US02				
Sheet	2	of	2		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	18	Grice, R., <i>et al.</i> , <i>J. Chem. Soc.</i> p. 1947-1954 (1963)	
	19	Hirota, S., <i>International J of Pharmaceutics</i> <u>162</u> (1-2):185-194, (1998).	
	20	Johnsson, M., <i>et al.</i> , <i>J of Liposome Res</i> <u>9</u> (1):53-79, (1999).	
	21	Kaneko, T., <i>et al.</i> , <i>Bioconjugate Chem.</i> <u>2</u> (3):133-141 (1991).	
	22	Kirpotin, D., <i>et al.</i> , <i>FEBS Letters</i> <u>388</u> :115-118, (1996).	
	23	Lash, L.H., <i>et al.</i> , <i>Arch. Biochem. Biophys.</i> <u>240</u> (2):583-592 (1985).	
	24	Mueller, C.E., <i>et al.</i> , <u>322</u> (6):343-350, (1989).	
	25	Senter, P.D., <i>et al.</i> , <i>J Org Chem</i> <u>55</u> (9):2975-2978, (1990).	
	26	Vaage, J., <i>et al.</i> , <i>Cancer</i> <u>72</u> (12):3671-3675, (1993).	
	27	Vaage, J., <i>et al.</i> , <i>Cancer</i> <u>73</u> (5):1478-1484, (1994).	
	28	Vaage, J., <i>et al.</i> , <i>International J of Cancer</i> <u>51</u> (6)942-948, ().	
	29	Veronese, <i>et al.</i> , <i>Applied Biochem. And Biotech.</i> p. 141-152 (1985).	
	30	Zalipsky, <i>et al.</i> , <i>Biotechnol. Appl. Biochem.</i> p. 100-114 (1992).	
	31	Zalipsky, <i>et al.</i> , <i>Eur. Polymer. J.</i> <u>19</u> (12):1177-1183 (1983).	
	32	Zalipsky, <i>et al.</i> , <i>Bioconj. Chem.</i> <u>4</u> (4):296-299 (1993).	
	33	Zalipsky, <i>Bioconj Chem</i> <u>10</u> (5):703-707, (1999).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	